金斯瑞生物科技(01548.HK)附屬傳奇生物於兩醫學組織披露項目臨床開發資料
金斯瑞生物科技(01548.HK)公布,其美國上市的非全資附屬公司傳奇生物披露,評估西達基奧崙賽的CARTITUDE臨床開發項目的最新資料將於2023年美國臨床腫瘤學會(ASCO)年會及2023年歐洲血液學協會(EHA)線上線下混合會議公布。
Legend-2(NCT03090659)的五年隨訪資料亦將於會上公布。Legend-2是一項2017年由研究者發起的評估類似嵌合抗原受體結構的臨床試驗,旨在評估LCAR-B38M CAR-T細胞用於復發或難治性多發性骨髓瘤患者的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.